Supplementary Box S1. The search strategy of PubMed

Source: PubMed Search on: February 28th, 2017 #1 ((("vitamin D"[Mesh] OR "cholecalciferol"[Mesh]) OR "25-hydroxyvitamin D"[Title/Abstract]) OR "25(OH)D"[Title/Abstract]) #2 ((("small for gestational age"[Title/Abstract] OR "small-for-gestationage"[Title/Abstract]) OR "small size for gestational age"[Title/Abstract]) OR SGA [Title/Abstract]) #3 #1 AND #2

The search strategy in other databases did some adjustments on the basis of the above database.

| A with one | Latitude | The time of year | Gestational age of | The prevalence | The prevalence of | Madaine I. a based in a dadara | Season of blood sample | |
|-------------------------|--|---|--------------------|----------------|----------------------|--|---------------------------------|--|
| Autnor | | data collected | infant at birth | of SGA | vitamin D deficiency | Maternal education status | | |
| I CC 1 15 | NA | 2003.2~2004.3 | 40.1±1.2 weeks | 9.2% | 23.1% | \leq 5 years (17.2%), 6-10years (38.5%), \geq 11 | Summer (43.6%) | |
| Leffelaar ¹³ | | | | | | years (44.3%) | | |
| Burris ²⁴ | NA | NA | 39.6 weeks | 4.8% | 32.4% | College graduate (41.2%) | NA | |
| Zhou ²⁵ | 23.1°N | 2010.9~2011.8 | NA | 0.6% | 18.9% | NA | NA | |
| Choi ²⁶ | 36.0°N | 2012.4~2013.9 | NA | 10.9% | 77.3% | ≤ 12 vacre(5.5%) > 12 vacre(04.5%) | Spring (44.5%), Summer (10.0%), | |
| | | | | | | ≈ 12 years(5.570), > 12 years(54.570) | Fall (39.5%), Winter (5.9%) | |
| Ong ¹⁸ | 1°22′N | NA | NA | 9.1% | 13.2% | Primary and secondary (30.2%), Post-secondary | NA | |
| | | | | | | (35.4%), University (34.4%) | | |
| Kiely ²⁷ | 52°N | 2008.3~2011.2 | NA | 10.7% | 44.0% | Secondary (61%), Tertiary (39%) | Winter (58.5%), Summer (41.5%) | |
| Scholl ²⁸ | NA | 2001~2007 | 38.5 | 7.2% | 33.7% | NA | NA | |
| Chen ⁴ | 31°52′N | 2008.11~2010.10 | NA | 8.9% | 38.41% | NA | Spring (36.7%), Summer (22.5%), | |
| | | | | | | NA | Fall (20.6%), Winter (20.2%) | |
| D1-29 | NA | 2005~2008 | NA | 9.9% | 21.5% | NA | Spring (20.5%), Summer (26.4%), | |
| Boyle | | | | | | NA | Fall (23.2%), Winter (29.8%) | |
| Berg ³⁰ | 52°22′N | 2003.2~2004.3 | 20-42 weeks | 9.1% | NA | NA | Winter (55.5%) | |
| Gerand ¹⁶ | ≥41°N(63.0%), | ≥41°N(63.0%), 1959~1965 N(28.8%), ≤35°N(8.2%) | 39.7±1.3 weeks | 18.4% | 34.8% | NA | Spring (25.9%), Summer (25.7%), | |
| | $38{\sim}40^{\circ}N(28.8\%), \leq 35^{\circ}N(8.2\%)$ | | | | | INA | Fall (24.6%), Winter (23.9%) | |
| Miliku ³¹ | NA | 2002.4~2006.1 | 35.9-42.3 weeks | 5.0% | 53.2% | No higher education (59.2%), Higher education | Spring (29.5%), Summer (22.9%), | |
| | | | | | | (40.8%) | Fall (24.0%), Winter (23.6%) | |
| Nobles ¹⁷ | NA | 2007~2012 | NA | 9.6% | 20.7% | \leq High school (55.2%), > High school (44.8%) | Summer (41.4%), Winter (58.7%) | |

|--|

NA : not available.

Supplementary Box S2. Quality assessment of cohort studies

NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE COHORT STUDIES

Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability

Selection

1) Representativeness of the exposed cohort

a) truly representative of the average _____ (describe) in the community *

b) somewhat representative of the average _____ in the community *****

c) selected group of users eg nurses, volunteers

d) no description of the derivation of the cohort

2) Selection of the non-exposed cohort

a) drawn from the same community as the exposed cohort *

b) drawn from a different source

c) no description of the derivation of the non-exposed cohort

3) Ascertainment of exposure

a) secure record (eg surgical records) *

b) structured interview *

c) written self-report

d) no description

4) Demonstration that outcome of interest was not present at start of study

a) yes 🟶

b) no

Comparability

1) Comparability of cohorts on the basis of the design or analysis

a) study controls for _____ (select the most important factor) *

b) study controls for any additional factor * (This criteria could be modified to indicate specific control for a second important factor.)

Outcome

1) Assessment of outcome

a) independent blind assessment *

b) record linkage *

c) self-report

d) no description

2) Was follow-up long enough for outcomes to occur

a) yes (select an adequate follow up period for outcome of interest) *

b) no

3) Adequacy of follow up of cohorts

a) complete follow up - all subjects accounted for *

b) subjects lost to follow up unlikely to introduce bias - small number lost - > _____% (select

an adequate %) follow up, or description provided of those lost) *

c) follow up rate < ____% (select an adequate %) and no description of those lost

d) no statement

| | Selection | | | | Comparability | | Outcome | | |
|-------------------------|----------------|----------------|-----------|---------------------|--------------------|------------|-----------------|--------------|--------|
| | Representative | Selection of | Ascertain | Demonstration that | Comparability of | Assessment | Was follow-up | Adequacy of | Total |
| Study | ness of the | the non- | ment of | outcome of interest | cohorts on the | of outcome | long enough for | follow up of | scores |
| | exposed cohort | exposed cohort | exposure | was not present at | basis of design or | | outcomes to | cohorts | |
| | | | | start of study | analysis | | occur | | |
| Leffelaar ¹⁴ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Burris ²³ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Zhou ²⁴ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |
| Choi ²⁵ | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 6 |
| Ong ¹⁷ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| Kiely ²⁶ | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 6 |
| Scholl ²⁷ | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 8 |
| Chen ⁴ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
| Boyle ²⁸ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Berg ²⁹ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Gerand ¹⁵ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
| Miliku ³⁰ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 7 |
| Nobles ¹⁶ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 |

Supplementary Table S2. Quality scores of included studies on vitamin D status and SGA.